{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:07:15Z","timestamp":1773097635912,"version":"3.50.1"},"reference-count":111,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The formation of an obstructive thrombus within an artery remains a major cause of mortality and morbidity worldwide. Despite effective inhibition of platelet function by modern antiplatelet therapies, these agents fail to fully eliminate atherothrombotic risk. This may well be related to extensive vascular disease, beyond the protective abilities of the treatment agents used. However, recent evidence suggests that residual vascular risk in those treated with modern antiplatelet therapies is related, at least in part, to impaired fibrin clot lysis. In this review, we attempt to shed more light on the role of hypofibrinolysis in predisposition to arterial vascular events. We provide a brief overview of the coagulation system followed by addressing the role of impaired fibrin clot lysis in acute and chronic vascular conditions, including coronary artery, cerebrovascular, and peripheral vascular disease. We also discuss the role of combined anticoagulant and antiplatelet therapies to reduce the risk of arterial thrombotic events, addressing both efficacy and safety of such an approach. We conclude that impaired fibrin clot lysis appears to contribute to residual thrombosis risk in individuals with arterial disease on antiplatelet therapy, and targeting proteins in the fibrinolytic system represents a viable strategy to improve outcome in this population. Future work is required to refine the antithrombotic approach by modulating pathological abnormalities in the fibrinolytic system and tailoring therapy according to the need of each individual.<\/jats:p>","DOI":"10.1055\/s-0040-1718923","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:27:16Z","timestamp":1618964836000},"page":"490-505","source":"Crossref","is-referenced-by-count":25,"title":["Fibrinolysis in Acute and Chronic Cardiovascular Disease"],"prefix":"10.1055","volume":"47","author":[{"given":"Noppadol","family":"Kietsiriroje","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom"},{"name":"Endocrinology and Metabolism Unit, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.S.","family":"Ari\u00ebns","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-3725","authenticated-orcid":false,"given":"Ramzi A.","family":"Ajjan","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015","volume":"70","author":"G A Roth","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jacc.2009.11.051","article-title":"A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques","volume":"55","author":"A J Reininger","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00016.2011","article-title":"New fundamentals in hemostasis","volume":"93","author":"H H Versteeg","year":"2013","journal-title":"Physiol Rev"},{"issue":"16","key":"ref4","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jacc.2015.02.040","article-title":"Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk","volume":"65","author":"O N Okafor","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"S 01","key":"ref5","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1111\/jth.12935","article-title":"Basic mechanisms and regulation of fibrinolysis","volume":"13","author":"C Longstaff","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jth.12455","article-title":"The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis","volume":"12","author":"E L Hethershaw","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00109-010-0691-5","article-title":"Platelet receptor signaling in thrombus formation","volume":"89","author":"D Stegner","year":"2011","journal-title":"J Mol Med (Berl)"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1055\/s-0037-1613368","article-title":"Molecular mechanisms of initiation of fibrinolysis by fibrin","volume":"89","author":"L Medved","year":"2003","journal-title":"Thromb Haemost"},{"issue":"51","key":"ref9","doi-asserted-by":"crossref","first-page":"15730","DOI":"10.1021\/bi001847a","article-title":"Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites","volume":"39","author":"S Yakovlev","year":"2000","journal-title":"Biochemistry"},{"issue":"13","key":"ref10","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"W Sumaya","year":"2018","journal-title":"Eur Heart J"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurheartj\/ehy656","article-title":"Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study","volume":"40","author":"M Farag","year":"2019","journal-title":"Eur Heart J"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2017-07-798306","article-title":"Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study","volume":"131","author":"J Cieslik","year":"2018","journal-title":"Blood"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00001721-199509000-00011","article-title":"Effect of fibrin structure on plasmin-mediated dissolution of plasma clots","volume":"6","author":"M E Carr Jr","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/01.ATV.20.5.1354","article-title":"Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy","volume":"20","author":"J P Collet","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"34","key":"ref15","doi-asserted-by":"crossref","first-page":"24259","DOI":"10.1016\/S0021-9258(18)35759-4","article-title":"The effect of fibrin structure on fibrinolysis","volume":"267","author":"D A Gabriel","year":"1992","journal-title":"J Biol Chem"},{"issue":"09","key":"ref16","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1538-7836.2007.02637.x","article-title":"Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine","volume":"5","author":"A Undas","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/01.ATV.0000241589.52950.4c","article-title":"Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis","volume":"26","author":"J P Collet","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2002-08-2527","article-title":"Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk","volume":"101","author":"A S Wolberg","year":"2003","journal-title":"Blood"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1160\/TH09-05-0306","article-title":"The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis","volume":"103","author":"S He","year":"2010","journal-title":"Thromb Haemost"},{"issue":"S 01","key":"ref20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jth.12229","article-title":"Fibrin(ogen) and thrombotic disease","volume":"11","author":"R A Ari\u00ebns","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/ATVBAHA.119.313626","article-title":"Effects of post-translational modifications of fibrinogen on clot formation, clot structure, and fibrinolysis: a systematic review","volume":"40","author":"J J de Vries","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.V100.3.743","article-title":"Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms","volume":"100","author":"R A Ari\u00ebns","year":"2002","journal-title":"Blood"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1538-7836.2004.01055.x","article-title":"Discovery of alpha2-plasmin inhibitor and its congenital deficiency","volume":"3","author":"N Aoki","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2010-01-263103","article-title":"Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men","volume":"116","author":"M E Meltzer","year":"2010","journal-title":"Blood"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/01.ATV.19.3.493","article-title":"Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study","volume":"19","author":"M Cushman","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ajh.21429","article-title":"Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality","volume":"84","author":"A R Folsom","year":"2009","journal-title":"Am J Hematol"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.ATV.0000249406.92992.0d","article-title":"Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study","volume":"26","author":"P E Morange","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00001721-200101000-00003","article-title":"Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin-alpha2-antiplasmin complex is an independent predictor of coronary re-events","volume":"12","author":"M Redondo","year":"2001","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00125-006-0197-4","article-title":"Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus","volume":"49","author":"E J Dunn","year":"2006","journal-title":"Diabetologia"},{"issue":"07","key":"ref30","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2337\/dc13-1776","article-title":"Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes","volume":"37","author":"A Agren","year":"2014","journal-title":"Diabetes Care"},{"issue":"S 01","key":"ref31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jth.12216","article-title":"Insights into thrombin activatable fibrinolysis inhibitor function and regulation","volume":"11","author":"J H Foley","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1055\/s-0037-1613349","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography","volume":"88","author":"V Schroeder","year":"2002","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.thromres.2010.11.026","article-title":"High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease","volume":"127","author":"E L de Bruijne","year":"2011","journal-title":"Thromb Res"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1538-7836.2009.03350.x","article-title":"The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study","volume":"7","author":"E L de Bruijne","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2008.002386","article-title":"Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men","volume":"94","author":"M E Meltzer","year":"2009","journal-title":"Haematologica"},{"issue":"05","key":"ref36","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/01.ATV.0000015445.22243.F4","article-title":"Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe","volume":"22","author":"I Juhan-Vague","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1046\/j.1538-7836.2003.00398.x","article-title":"Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study","volume":"1","author":"I Juhan-Vague","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1538-7836.2008.03221.x","article-title":"Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study","volume":"7","author":"D A Tregouet","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0038-1650232","article-title":"Proteins of the fibrinolytic system in human thrombi","volume":"75","author":"L A Robbie","year":"1996","journal-title":"Thromb Haemost"},{"issue":"24","key":"ref40","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJM200006153422406","article-title":"Plasminogen-activator inhibitor type 1 and coronary artery disease","volume":"342","author":"H P Kohler","year":"2000","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.02.135","article-title":"Role of plasminogen activator inhibitor-1 in coronary pathophysiology","volume":"164","author":"R G Jung","year":"2018","journal-title":"Thromb Res"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1055\/s-0038-1645691","article-title":"Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1","volume":"63","author":"T Urano","year":"1990","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00125-014-3267-z","article-title":"Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3","volume":"57","author":"K Hess","year":"2014","journal-title":"Diabetologia"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/01.CIR.85.1.305","article-title":"Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis","volume":"85","author":"M Levi","year":"1992","journal-title":"Circulation"},{"issue":"24","key":"ref45","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jacc.2009.11.095","article-title":"Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease","volume":"55","author":"D A Gorog","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/JAHA.116.004918","article-title":"Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease","volume":"6","author":"C Song","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"ref47","doi-asserted-by":"crossref","first-page":"18831","DOI":"10.1074\/jbc.M111.323287","article-title":"Plasminogen is a complement inhibitor","volume":"287","author":"D Barthel","year":"2012","journal-title":"J Biol Chem"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00125-011-2301-7","article-title":"A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3","volume":"55","author":"K Hess","year":"2012","journal-title":"Diabetologia"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/eurheartj\/ehz745.0073","article-title":"Complement activation leads to C3 and C5 dependent prothrombotic alterations of fibrin clots","volume":"40","author":"K A Schutt","year":"2019","journal-title":"Eur Heart J"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1160\/TH05-06-0384","article-title":"Complement C3 and C-reactive protein levels in patients with stable coronary artery disease","volume":"94","author":"R Ajjan","year":"2005","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"D P Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"05","key":"ref52","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"M B Boffa","year":"2016","journal-title":"J Lipid Res"},{"issue":"05","key":"ref53","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1538-7836.2006.01903.x","article-title":"Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis","volume":"4","author":"A Undas","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1016\/S0021-9258(18)52266-3","article-title":"Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis","volume":"266","author":"O R Etingin","year":"1991","journal-title":"J Biol Chem"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(96)05971-0","article-title":"Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells","volume":"128","author":"S Ren","year":"1997","journal-title":"Atherosclerosis"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"M B Boffa","year":"2019","journal-title":"J Lipid Res"},{"issue":"05","key":"ref57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ijlh.12688","article-title":"Global assays of fibrinolysis","volume":"39","author":"A Ilich","year":"2017","journal-title":"Int J Lab Hematol"},{"issue":"02","key":"ref58","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.atherosclerosis.2007.05.028","article-title":"Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress","volume":"196","author":"A Undas","year":"2008","journal-title":"Atherosclerosis"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1160\/TH16-10-0496","article-title":"Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention","volume":"117","author":"R P Kreutz","year":"2017","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1160\/TH16-09-0712","article-title":"Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention","volume":"117","author":"C Christopoulos","year":"2017","journal-title":"Thromb Haemost"},{"issue":"19","key":"ref61","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","article-title":"Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction","volume":"55","author":"S Saraf","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.thromres.2009.11.013","article-title":"Fibrin clot properties in acute ischemic stroke: relation to neurological deficit","volume":"125","author":"A Undas","year":"2010","journal-title":"Thromb Res"},{"issue":"07","key":"ref63","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1160\/TH16-12-0954","article-title":"Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome","volume":"117","author":"J P Bembenek","year":"2017","journal-title":"Thromb Haemost"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.thromres.2020.01.008","article-title":"A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause","volume":"187","author":"I A Karpi\u0144ska","year":"2020","journal-title":"Thromb Res"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s11239-019-01826-9","article-title":"Restenosis is associated with prothrombotic plasma fibrin clot characteristics in endovascularly treated patients with critical limb ischemia","volume":"47","author":"T Nowakowski","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"05","key":"ref66","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.thromres.2013.03.015","article-title":"Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay","volume":"131","author":"C J Reddel","year":"2013","journal-title":"Thromb Res"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2141.2011.08935.x","article-title":"Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study","volume":"156","author":"B Siegerink","year":"2012","journal-title":"Br J Haematol"},{"issue":"08","key":"ref68","doi-asserted-by":"crossref","first-page":"e71150","DOI":"10.1371\/journal.pone.0071150","article-title":"Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure","volume":"8","author":"S Neergaard-Petersen","year":"2013","journal-title":"PLoS One"},{"issue":"05","key":"ref69","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3109\/09537100903548903","article-title":"Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study","volume":"21","author":"U S Tantry","year":"2010","journal-title":"Platelets"},{"issue":"02","key":"ref70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/09537100802687666","article-title":"The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting","volume":"20","author":"P A Gurbel","year":"2009","journal-title":"Platelets"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5582\/bst.2016.01233","article-title":"Relationship between thromboelastography and long-term ischemic events as gauged by the response to clopidogrel in patients undergoing elective percutaneous coronary intervention","volume":"11","author":"X Hou","year":"2017","journal-title":"Biosci Trends"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-0039-1700873","article-title":"Imbalance between fibrin clot formation and fibrinolysis predicts cardiovascular events in patients with stable coronary artery disease","volume":"120","author":"S Neergaard-Petersen","year":"2020","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref73","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.thromres.2006.08.005","article-title":"Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia","volume":"120","author":"S Anzej","year":"2007","journal-title":"Thromb Res"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1161\/STROKEAHA.108.532812","article-title":"Altered fibrin clot structure\/function in patients with cryptogenic ischemic stroke","volume":"40","author":"A Undas","year":"2009","journal-title":"Stroke"},{"issue":"S 01","key":"ref75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2298\/SARH10S1012V","article-title":"Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients","volume":"138","author":"B A Vuckovi\u0107","year":"2010","journal-title":"Srp Arh Celok Lek"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/neurintsurg-2015-011687","article-title":"Association of thrombelastographic parameters with post-stenting ischemic events","volume":"9","author":"B Wang","year":"2017","journal-title":"J Neurointerv Surg"},{"issue":"02","key":"ref77","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.atherosclerosis.2010.12.040","article-title":"Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans","volume":"215","author":"A Undas","year":"2011","journal-title":"Atherosclerosis"},{"issue":"12","key":"ref78","doi-asserted-by":"crossref","first-page":"608","DOI":"10.20452\/pamw.1535","article-title":"Altered fibrin clot properties in patients with premature peripheral artery disease","volume":"122","author":"A Okraska-Bylica","year":"2012","journal-title":"Pol Arch Med Wewn"},{"issue":"06","key":"ref79","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jvs.2008.07.010","article-title":"Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication","volume":"48","author":"N Bhasin","year":"2008","journal-title":"J Vasc Surg"},{"issue":"04","key":"ref80","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jvs.2008.11.028","article-title":"Regarding \u201cAltered fibrin clot structure and function in individuals with intermittent claudication\u201d","volume":"49","author":"N Bhasin","year":"2009","journal-title":"J Vasc Surg"},{"issue":"11","key":"ref81","doi-asserted-by":"crossref","first-page":"e27852","DOI":"10.1371\/journal.pone.0027852","article-title":"Anticoagulants and the propagation phase of thrombin generation","volume":"6","author":"T Orfeo","year":"2011","journal-title":"PLoS One"},{"issue":"01","key":"ref82","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11239-019-01851-8","article-title":"A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor","volume":"48","author":"Y Morishima","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-0039-1695772","article-title":"Effects of edoxaban on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel: results of the EDOX-APT study","volume":"120","author":"F Franchi","year":"2020","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref84","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11239-019-02014-5","article-title":"Rationale and design of \u201cCan Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)\u201d study: a randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome","volume":"49","author":"Y X Gue","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"01","key":"ref85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"J L Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"08","key":"ref86","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"J H Alexander","year":"2011","journal-title":"N Engl J Med"},{"issue":"14","key":"ref87","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"J W Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"ref88","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial","volume":"71","author":"S S Anand","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref89","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCRESAHA.118.313141","article-title":"Synergy of dual pathway inhibition in chronic cardiovascular disease","volume":"124","author":"M Coppens","year":"2019","journal-title":"Circ Res"},{"issue":"04","key":"ref90","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1538-7836.2010.03739.x","article-title":"Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor","volume":"8","author":"C T Ammollo","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10238-018-0490-9","article-title":"Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation","volume":"18","author":"O K\u00f6nigsbr\u00fcgge","year":"2018","journal-title":"Clin Exp Med"},{"issue":"04","key":"ref92","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/rth2.12120","article-title":"Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots","volume":"2","author":"S Salta","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1160\/th15-06-0467","article-title":"Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study","volume":"115","author":"F Franchi","year":"2016","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref94","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"ref95","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"J Oldgren","year":"2011","journal-title":"Eur Heart J"},{"issue":"05","key":"ref96","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"K Uchino","year":"2012","journal-title":"Arch Intern Med"},{"issue":"12","key":"ref97","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1111\/j.1538-7836.2009.03596.x","article-title":"Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?","volume":"7","author":"J L Willemse","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref98","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.drudis.2014.05.025","article-title":"Novel or expanding current targets in fibrinolysis","volume":"19","author":"T Wyseure","year":"2014","journal-title":"Drug Discov Today"},{"issue":"01","key":"ref99","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-017-0515-9","article-title":"Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk","volume":"16","author":"K Kearney","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"04","key":"ref100","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.thromres.2011.11.038","article-title":"Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1","volume":"129","author":"B Van De Craen","year":"2012","journal-title":"Thromb Res"},{"issue":"05","key":"ref101","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/jcbfm.2009.272","article-title":"A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates","volume":"30","author":"Y Izuhara","year":"2010","journal-title":"J Cereb Blood Flow Metab"},{"issue":"06","key":"ref102","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1160\/TH16-04-0306","article-title":"Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1","volume":"116","author":"X Zhou","year":"2016","journal-title":"Thromb Haemost"},{"issue":"14","key":"ref103","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1021\/jm049766q","article-title":"Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization","volume":"47","author":"H Elokdah","year":"2004","journal-title":"J Med Chem"},{"issue":"07","key":"ref104","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1517\/13543776.2013.782393","article-title":"Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present)","volume":"23","author":"Y M Fortenberry","year":"2013","journal-title":"Expert Opin Ther Pat"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ejmech.2015.01.010","article-title":"Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview","volume":"92","author":"A Rouch","year":"2015","journal-title":"Eur J Med Chem"},{"issue":"08","key":"ref106","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2014-07-588319","article-title":"Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke","volume":"125","author":"T Wyseure","year":"2015","journal-title":"Blood"},{"issue":"11","key":"ref107","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.116.024421","article-title":"Releasing the brakes on the fibrinolytic system in pulmonary emboli: unique effects of plasminogen activation and \u03b12-antiplasmin inactivation","volume":"135","author":"S Singh","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"ref108","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nbt1342","article-title":"Complement-targeted therapeutics","volume":"25","author":"D Ricklin","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"S 01","key":"ref109","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0140-6736(15)60372-5","article-title":"Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes","volume":"385","author":"R King","year":"2015","journal-title":"Lancet"},{"issue":"01","key":"ref110","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood-2013-04-494641","article-title":"Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity","volume":"122","author":"R A Ajjan","year":"2013","journal-title":"Blood"},{"issue":"01","key":"ref111","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.2008.07569.x","article-title":"Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men","volume":"145","author":"M E Meltzer","year":"2009","journal-title":"Br J Haematol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1718923.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T21:57:32Z","timestamp":1724882252000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1718923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":111,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2021,6,30]]},"published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1718923","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}